EUVIMEDEUVIMED entdecken
EditorialOpen Access

Spotlighting Structural Constraints on Decisions About Participation in Genomic and Precision Medicine

Deanne Dunbar Dolan iD, Mildred K Cho iD, Sandra Soo-Jin Lee iD

AJOB Empirical Bioethics · 2024

DOI: 10.1080/23294515.2024.2355893 ↗

Kurz gefasst

Editorial in der Zeitschrift AJOB Empirical Bioethics, 2024. Verfasst von Deanne Dunbar Dolan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for ELSI Resources and Analysis (CERA), Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Precision Medicine, Genomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS, National Human Genome Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Public investments in genomic and precision medicine have begun to yield clinically useful interventions, most recently, for example, two new, FDA-approved gene therapies for sickle cell disease (FDA, 2023).However, there are doubts about whether everyone will derive the same benefit from translational innovations or have a fair chance at being able to access them (Dolan, Cho, and Lee 2023).Patients with low incomes and those who are members of underserved racial and ethnic groups in the U.S. are already experiencing disparities and delays in access to genetic services (McCarthy et al., 2016;Gene Hallford et al. 2020;Chapman-Davis et al. 2021;Fraiman and Wojcik 2021;Omorodion et al. 2022), which can be partly explained by inadequate preparation for genomic medicine at the health system and provider levels (NASEM 2018).At the level of the health system, for example, genomic services delivery systems that rely on the existence of electronic health records (EHR) do not well serve individuals who receive care from multiple health systems or community-based healthcare organizations without EHRs (Williams et al., 2018).At the provider level, the primary care workforce lacks confidence in its ability to counsel patients about genetic risk and management and fears that surfacing genetic information will result in social and insurance discrimination for its patients (Mikat-Stevens, Larson, & Tarini, 2015;Hauser et al., 2018).There is also a need to implement resolutions to the workforce shortages that limit access to genetic services in areas of the country where there are few geneticists (Jenkins et al. 2012;Maiese et al.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineGenomicsHumansDecision MakingPatient ParticipationGenetic Testing

Autor:innen und Institutionen

  • Center for ELSI Resources and Analysis (CERA), Stanford University School of Medicine, Stanford, California, USA.
  • Stanford Center for Biomedical Ethics, Stanford University School of Medicine, Stanford, California, USA.
  • Division of Ethics, Department of Medical Humanities & Ethics, Columbia University, New York, New York, USA.

ORCID-Profile: Deanne Dunbar Dolan, Mildred K Cho, Sandra Soo-Jin Lee

Förderung

  • NHGRI NIH HHS
  • National Human Genome Research Institute

Zitieren

APA

Dolan, D. D., Cho, M. K., & Lee, S. S. (2024). Spotlighting Structural Constraints on Decisions About Participation in Genomic and Precision Medicine. AJOB Empirical Bioethics. https://doi.org/10.1080/23294515.2024.2355893

Vancouver

Dolan DD, Cho MK, Lee SS. Spotlighting Structural Constraints on Decisions About Participation in Genomic and Precision Medicine. AJOB Empirical Bioethics. 2024. doi:10.1080/23294515.2024.2355893

BibTeX
@article{Dolan2024,
  author = {Dolan, Deanne Dunbar and Cho, Mildred K and Lee, Sandra Soo-Jin},
  title = {Spotlighting Structural Constraints on Decisions About Participation in Genomic and Precision Medicine},
  journal = {AJOB Empirical Bioethics},
  year = {2024},
  doi = {10.1080/23294515.2024.2355893}
}
Kostenlos starten →